3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Uveal Melanoma
1
Thyroid Carcinoma, Anaplastic
1
Melanoma
1
Healthy Adult Male
1
Healthy
1
Interventions
dabrafenib
2
Trastuzumab
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
trametinib
1
tipifarnib
1
mercaptoundecahydrododecaborate
1
durvalumab
1
cemiplimab
1
Semaxinib
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Paclitaxel
1
PLX8394
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Docetaxel
1
Adalimumab
1
4-boronophenylalanine-fructose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Thyroid Carcinoma, Anaplastic
×
Adalimumab
×
Clear all
NCT02516774
2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Withdrawn